-
公开(公告)号：US20170334999A1
公开(公告)日：2017-11-23
申请号：US15522061
申请日：2015-10-30
IPC分类号： C07K16/28 , A61K39/395 , C07K16/30
CPC分类号： C07K16/2827 , A61K39/3955 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K16/3015 , C07K16/3023 , C07K16/3046 , C07K16/3069 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： Provided herein are embodiments relating to therapeutic applications of B7-H4 antibodies.
-
公开(公告)号：US20170307622A1
公开(公告)日：2017-10-26
申请号：US15616192
申请日：2017-06-07
发明人： ROBERT A. STULL , LAURA SAUNDERS , SCOTT J. DYLLA , ORIT FOORD , DAVID LIU , MICHAEL TORGOV , HUI SHAO
IPC分类号： G01N33/574 , A61K39/395 , A61K45/06 , A61K51/10 , C07K16/18 , C07K16/28 , C07K16/30 , A61K31/551 , A61K31/5517 , A61K39/00
CPC分类号： A61K47/6803 , A61K31/551 , A61K31/5517 , A61K39/3955 , A61K45/06 , A61K47/48384 , A61K47/48407 , A61K47/48469 , A61K47/48538 , A61K47/48561 , A61K47/48592 , A61K47/48638 , A61K47/48715 , A61K47/48723 , A61K47/6809 , A61K47/6811 , A61K47/6813 , A61K47/6825 , A61K47/6829 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K47/6891 , A61K51/1096 , A61K2039/505 , A61K2039/572 , C07D487/04 , C07D487/16 , C07K16/18 , C07K16/28 , C07K16/2809 , C07K16/30 , C07K16/3023 , C07K16/3069 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/70 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/30 , G01N33/57423 , G01N33/57492 , G01N2333/70596
摘要： Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
-
公开(公告)号：US20170306035A1
公开(公告)日：2017-10-26
申请号：US15474731
申请日：2017-03-30
发明人： Zhehong CAI , Indrani CHAKRABORTY , Marie-Michelle Navarro GARCIA , Thomas D. KEMPE , Alan J. KORMAN , Alexander T. KOZHICH , Hadia LEMAR , Mark MAURER , Christina Maria MILBURN , Michael QUIGLEY , Xiang SHAO , Mohan SRINIVASAN , Kent THUDIUM , Susan Chien-Szu WONG , Jochem GOKEMEIJER , Xi-Tao WANG , Han CHANG , Patrick GUIRNALDA
CPC分类号： C07K16/2878 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/574 , G01N2333/70514
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
24.发明申请公开(公告)号：US20170298132A1
公开(公告)日：2017-10-19
申请号：US15623572
申请日：2017-06-15
申请人： INNATE PHARMA
发明人： CECILE BONNAFOUS , HELENE SICARD , RENAUD BUFFET
IPC分类号： C07K16/28 , G01N33/574 , C07K16/30 , A61K39/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/3023 , C07K16/3061 , C07K2317/33 , C07K2317/34 , C07K2317/732 , G01N33/57426 , G01N2333/705 , G01N2333/70503
摘要： The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
-
公开(公告)号：US20170266313A1
公开(公告)日：2017-09-21
申请号：US15608991
申请日：2017-05-30
发明人： ROBERT A. STULL , LAURA SAUNDERS , SCOTT J. DYLLA , ORIT FOORD , DAVID LIU , MICHAEL TORGOV , HUI SHAO
IPC分类号： A61K31/551 , A61K31/5517 , A61K39/395 , A61K45/06 , A61K51/10 , C07K16/18 , C07K16/28 , C07K16/30 , G01N33/574 , A61K39/00
CPC分类号： A61K47/6803 , A61K31/551 , A61K31/5517 , A61K39/3955 , A61K45/06 , A61K47/48384 , A61K47/48407 , A61K47/48469 , A61K47/48538 , A61K47/48561 , A61K47/48592 , A61K47/48638 , A61K47/48715 , A61K47/48723 , A61K47/6809 , A61K47/6811 , A61K47/6813 , A61K47/6825 , A61K47/6829 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K47/6891 , A61K51/1096 , A61K2039/505 , A61K2039/572 , C07D487/04 , C07D487/16 , C07K16/18 , C07K16/28 , C07K16/2809 , C07K16/30 , C07K16/3023 , C07K16/3069 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/70 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/30 , G01N33/57423 , G01N33/57492 , G01N2333/70596
摘要： Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
-
26.发明申请公开(公告)号：US20170258905A1
公开(公告)日：2017-09-14
申请号：US15402888
申请日：2017-01-10
发明人： Asher Nathan , Michal Shahar
IPC分类号： A61K39/395 , A61K38/16 , C07K16/28 , C07K14/31 , C07K16/30
CPC分类号： A61K39/39558 , A61K38/164 , A61K39/085 , A61K39/39541 , A61K39/3955 , A61K47/6829 , A61K47/6851 , A61K2039/505 , A61K2039/507 , A61K2039/585 , A61K2039/6056 , A61K2039/86 , C07K14/31 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3053 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2319/40 , C07K2319/55 , C07K2319/74 , A61K2300/00
摘要： The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).
-
公开(公告)号：US20170253665A1
公开(公告)日：2017-09-07
申请号：US15432180
申请日：2017-02-14
发明人： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria N. JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard HUANG , Martin J. CORBETT , Joseph E. MYERS, JR. , Liang SCHWEIZER , Sandra V. HATCHER , Haichun HUANG , Pingping ZHANG
IPC分类号： C07K16/40 , G01N33/573 , A61K39/395 , A61K45/06 , C07K16/30
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US09738725B2
公开(公告)日：2017-08-22
申请号：US14166251
申请日：2014-01-28
发明人： Dennis E. Hallahan , Heping Yan
IPC分类号： A61K38/00 , A61K39/00 , A61K39/395 , A61K49/00 , A61K51/10 , C07K16/18 , C07K16/30 , A61N5/10 , A61B90/00
CPC分类号： C07K16/30 , A61B5/4848 , A61B6/032 , A61B6/463 , A61B6/481 , A61B6/508 , A61B90/361 , A61K39/3955 , A61K49/0058 , A61K51/1045 , A61K51/1066 , A61K51/1093 , A61N5/10 , A61N2005/1087 , A61N2005/1098 , C07K16/18 , C07K16/3023 , C07K16/3053 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/94
摘要： The present invention is directed towards isolated antibodies that bind to GRP78 and TIP-1.
-
公开(公告)号：US09725519B2
公开(公告)日：2017-08-08
申请号：US14561944
申请日：2014-12-05
发明人： Takashi Masuko , Shinichiro Niwa , Hidemi Hayashi , Dai Ogura , Takayuki Shindou
IPC分类号： C07K16/30 , G01N33/574 , A61K39/395 , C07K16/28 , A61K35/17 , A61K47/48 , A61K51/10
CPC分类号： C07K16/30 , A61K35/17 , A61K47/6851 , A61K51/1045 , C07K16/2896 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/73 , C07K2317/732 , C07K2317/77 , G01N33/57492 , G01N2333/70596
摘要： The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains an antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
-
公开(公告)号：US20170209574A1
公开(公告)日：2017-07-27
申请号：US15515469
申请日：2015-10-02
申请人： Zhu Alexander Cao , Xianhui Rong , Maria Consuelo Pinzon-Ortiz , Tyler Longmire , Benjamin Hyun Lee , Novartis AG
发明人： Zhu Alexander Cao , Xianhui Rong , Maria Consuelo Pinzon-Ortiz , Tyler Longmire , Benjamin Hyun Lee
IPC分类号： A61K39/395 , C07K16/30 , A61K9/00 , A61K31/427 , A61K31/55 , A61K31/496 , A61K31/444 , A61K31/4045 , A61K31/519 , A61K31/506 , C07K16/28 , A61K31/436
CPC分类号： A61K39/39558 , A61K9/0019 , A61K9/0053 , A61K31/4045 , A61K31/427 , A61K31/436 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/55 , A61K39/39541 , A61K45/06 , A61K2039/505 , A61P35/00 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/76 , G01N33/574 , A61K2300/00
摘要： Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. The combination may comprise an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is an inhibitor of an immune checkpoint molecule chosen from the list of inhibitors of one or more of PD-1, PD L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or the immunomodulator is an activator of a costimulatory molecule chosen from the list of agonists of one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand, and wherein (ii) the second therapeutic agent is chosen from one or more compounds as provided in Table 1, i.e. LCL 161, Rad-001 (Evrolimus), CGM097, LGH-447, LJM716 (Human monoclonal antibody), LB-H589 (Panobinostat), INC424 (Ruxolitinib), BUW078 or BGJ398.
-
-
-
-
-
-
-
-
-
搜索结果
936 条记录 (耗时 0.076 秒)
